Replimune Group Inc. (REPL) is a clinical-stage biotechnology company that develops oncolytic immunotherapies for the treatment of cancer. The company's lead product candidate, RP1, is an intratumoral immune activator that uses a proprietary engineered herpes simplex virus (HSV) to selectively infect and replicate within tumor cells, leading to their destruction and the release of tumor-associated antigens. RP1 is being evaluated in clinical trials for the treatment of multiple types of solid tumors, including melanoma, head and neck cancer, and non-muscle invasive bladder cancer. Replimune is also developing other oncolytic immunotherapies, including RP2, RP3, and RP4, that utilize similar viral vectors and immune modulators. The company is headquartered in Woburn, Massachusetts, and as of September 2021, had a market capitalization of approximately $1.87 billion.
Replimune Group Inc. (REPL) is a clinical-stage biotechnology company that develops oncolytic immunotherapies for the treatment of cancer. The company's lead product candidate, RP1, is an intratumoral immune activator that uses a proprietary engineered herpes simplex virus (HSV) to selectively infect and replicate within tumor cells, leading to their destruction and the release of tumor-associated antigens. RP1 is being evaluated in clinical trials for the treatment of multiple types of solid tumors, including melanoma, head and neck cancer, and non-muscle invasive bladder cancer. Replimune is also developing other oncolytic immunotherapies, including RP2, RP3, and RP4, that utilize similar viral vectors and immune modulators. The company is headquartered in Woburn, Massachusetts, and as of September 2021, had a market capitalization of approximately $1.87 billion.